Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-07-23
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the clinical response and safety of CMAB009
plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and
oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai Zhangjiang Biotechnology Limited Company
Collaborators:
Shanghai Biomabs Pharmaceutical Co., Ltd. Shanghai Biomabs Pharmaceuticals Co Ltd